Thalidomide in the treatment of relapsed and refractory myeloma.

被引：0
|
作者：
Rajkumar, SV [1 ]
Fonseca, R [1 ]
Dispenzieri, A [1 ]
Lacy, MQ [1 ]
Witzig, TE [1 ]
Lust, JA [1 ]
Kyle, RA [1 ]
Gertz, MA [1 ]
Greipp, PR [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1414
引用
收藏
页码：316A / 316A
页数：1
相关论文
共 50 条
  • [21] Thalidomide in the treatment of relapsed multiple myeloma
    Rajkumar, SV
    Fonseca, R
    Dispenzieri, A
    Lacy, MQ
    Lust, JA
    Witzig, TE
    Kyle, RA
    Gertz, MA
    Greipp, PR
    MAYO CLINIC PROCEEDINGS, 2000, 75 (09) : 897 - 901
  • [22] Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma
    Schmielau, J
    Teschendorf, C
    König, M
    Schmiegel, W
    Graeven, U
    LEUKEMIA & LYMPHOMA, 2005, 46 (04) : 567 - 569
  • [23] Clinical study of fludarabine, mitoxantrone, and dexamethasone in the treatment of refractory or relapsed multiple myeloma.
    Luo, SK
    Li, J
    Hong, WD
    Zhao, Y
    Tong, XZ
    BLOOD, 2005, 106 (11) : 380B - 380B
  • [24] Pad in relapsed and refractory myeloma. a phase II study
    Morris, T. C. M.
    Drake, M.
    Kettle, P. J.
    Brunton, A.
    Cook, G.
    Leahy, M.
    O'Dwyer, M.
    Enright, H.
    O'Shea, T.
    Popat, R.
    Cavenagh, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 160 - 160
  • [25] PAD is a highly effective regimen for the treatment of patients with relapsed refractory multiple myeloma.
    Delforge, Michel
    Janssens, Ann
    Dierickx, Dann
    Maertens, Johan
    Theunissen, Koen
    Vandenberghe, Peter
    Verhoef, Gregor
    BLOOD, 2006, 108 (11) : 363B - 363B
  • [26] Pulsed oral dexamethasone in relapsed and refractory multiple myeloma.
    Smith, AG
    Crofts, SE
    WhatelySmith, C
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 310 - 310
  • [27] Low dose thalidomide for the treatment of multiple myeloma.
    Bittencourt, R
    Almeida, AD
    Friederich, JR
    Fernande, F
    Fogliatto, L
    Paz, A
    Astigarraga, C
    Leugeur, D
    Silla, L
    BLOOD, 2005, 106 (11) : 370B - 370B
  • [28] Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (Hyper-CDT) in primary refractory or relapsed multiple myeloma.
    Kropff, MH
    Innig, G
    Mitterer, M
    Straka, C
    Ostermann, H
    Koch, OM
    Berdel, WE
    Kienast, J
    BLOOD, 2000, 96 (11) : 168A - 168A
  • [29] Treatment of relapsed and refractory myeloma
    Reece, Donna E.
    Leitch, Heather A.
    Atkins, Harold
    Voralia, Michael
    Canning, Leah A.
    LeBlanc, Richard
    Belch, Andrew R.
    White, Darrell
    Kovacs, Michael J.
    LEUKEMIA & LYMPHOMA, 2008, 49 (08) : 1470 - 1485
  • [30] Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma.
    Plesner, Torben
    Arkenau, Hendrik-Tobias
    Lokhorst, Henk M.
    Gimsing, Peter
    Krejcik, Jakub
    Lemech, Charlotte Rose
    Minnema, Monique
    Lassen, Ulrik Niels
    Ahmadi, Tahamtan
    Yeh, Howard
    Guckert, Mary
    Brun, Nikolai C.
    Lisby, Steen
    Basse, Linda
    Palumbo, Antonio
    Richardson, Paul G.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345